Skip to content
value.today

NantBioscience, Inc.

Formerly NantBio, Inc., NantBio, LLC, Nant Discovery & Development, LLC

Total raised
$105 M
4 rounds on record
Latest round
$10 M
Apr 2015
First round on record
Jan 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of NantBioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2023$75 MIssued in a merger or acquisition$50 to $250 million

NantBioscience, Inc.: Private sale, Nov 2023

Investors in this round

6 investors had bought by the notice of Nov 13, 2023: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Kenworthy · Executive Officer, Director · Secretary
  • James Banaag · Executive Officer · Chief Financial Officer
  • Patrick Soon-Shiong · Executive Officer, Director · President, Chief Executive Officer
  • Douglas Reed Maughan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Banaag, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 13, 2023. Read the notice at the SEC.

equity, debtSEC
Apr 2015$10 MNo. 4$10 to $50 million

NantBioscience, Inc.: Raise no. 4, Apr 2015

Investors in this round

1 investor had bought by the notice of Jun 2, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick Shoon-Shiong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles C. Kim, General Counsel. Source: SEC Form D and 1 amendment, newest notice filed Jun 2, 2015. Read the notice at the SEC.

equitySEC
Oct 2014$25 MNo. 3$10 to $50 million

NantBioscience, Inc.: Raise no. 3, Oct 2014

Investors in this round

1 investor had bought by the notice of Oct 30, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $100 M offered; $75 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick Soon-Shiong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles C. Kim, General Counsel. Source: SEC Form D, newest notice filed Oct 30, 2014. Read the notice at the SEC.

equitySEC
Jul 2014$45 MNo. 2$10 to $50 million

NantBioscience, Inc.: Raise no. 2, Jul 2014

Investors in this round

1 investor had bought by the notice of Feb 6, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$45 M of $45 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick Shoon-Shiong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles C. Kim, General Counsel. Source: SEC Form D, newest notice filed Feb 6, 2015. Read the notice at the SEC.

equitySEC
Jan 2014$25 MNo. 1$10 to $50 million

NantBioscience, Inc.: Raise no. 1, Jan 2014

Investors in this round

1 investor had bought by the notice of May 16, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick Soon-Shiong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles C. Kim, General Counsel. Source: SEC Form D, newest notice filed May 16, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NantBioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2023).

    SEC Form D · Nov 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Nov 2023

That is all the official record says: NantBioscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of NantBioscience, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NantBioscience, Inc.
NameRoleNamed in
Charles KenworthySecretaryNov 2023
James BanaagChief Financial OfficerNov 2023
Patrick Soon-ShiongPresident, Chief Executive OfficerNov 2023
Charles KenworthySecretaryNov 2023
Douglas Reed MaughanDirectorNov 2023
Patrick Soon-ShiongPresident, Chief Executive OfficerNov 2023
Patrick Shoon-ShiongDirectorJun 2015